REMINDER: Our hotline team is working remotely and focusing their time on helping our patients.  We kindly ask pharmacies, providers, and their staff to use our Pharmacy and Provider Portals. Please note: if you are contacting us about a payment or grant, it is faster to email us at grants@healthwellfoundation.org. We appreciate your continued patience and look forward to continuing to serve you. Wishing you all safety and good health during this difficult time. The HealthWell Team

 

 

Dismiss alert
By Emily Burke, Ph.D., Director of Instruction, BiotechPrimer.com  |  Mar 11, 2020

Search & Destroy: Chimeric Antigen Receptor T-Cells (CAR-T)

Editor’s Note: The following article is reprinted, with permission from Biotech Primer. The original version appeared in the Biotech Primer WEEKLY. To subscribe to the Biotech Primer WEEKLY, click here. The first (and so far, only) chimeric antigen receptor T-cell (CAR-T) therapies—tisagenlecleucel and axicabtagene ciloleucel were approved in 2017, and…more.

Close menu